Invivyd’s (IVVD) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Invivyd (NASDAQ:IVVD) in a research note published on Tuesday,Benzinga reports. They currently have a $10.00 price objective on the stock. HC Wainwright also issued estimates for Invivyd’s Q4 2024 earnings at ($0.36) EPS, FY2024 earnings at ($1.64) EPS and FY2029 earnings at $0.41 EPS.

IVVD has been the topic of several other reports. Morgan Stanley cut their price objective on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research report on Wednesday, November 20th. EF Hutton Acquisition Co. I upgraded Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, D. Boral Capital reiterated a “buy” rating and set a $9.00 price objective on shares of Invivyd in a report on Monday. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Invivyd currently has an average rating of “Buy” and a consensus target price of $7.89.

Invivyd Stock Performance

Shares of IVVD stock opened at $1.98 on Tuesday. Invivyd has a 52 week low of $0.35 and a 52 week high of $5.10. The company’s 50 day moving average price is $0.55 and its two-hundred day moving average price is $0.83. The company has a market capitalization of $236.85 million, a P/E ratio of -1.01 and a beta of 0.61.

Insider Transactions at Invivyd

In related news, Director Terrance Mcguire sold 160,400 shares of the company’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $0.59, for a total transaction of $94,636.00. Following the sale, the director now owns 4,202,679 shares in the company, valued at approximately $2,479,580.61. This represents a 3.68 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 816,466 shares of company stock worth $423,214 in the last three months. Insiders own 17.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in IVVD. Proficio Capital Partners LLC acquired a new stake in shares of Invivyd in the 3rd quarter valued at approximately $27,000. Marshall Wace LLP lifted its stake in Invivyd by 4.2% in the second quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock valued at $866,000 after acquiring an additional 31,992 shares during the last quarter. State Street Corp grew its position in shares of Invivyd by 3.7% in the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock valued at $1,039,000 after acquiring an additional 35,904 shares during the period. Cubist Systematic Strategies LLC increased its stake in shares of Invivyd by 66.1% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock worth $148,000 after purchasing an additional 53,499 shares during the last quarter. Finally, Barclays PLC raised its holdings in shares of Invivyd by 179.6% in the 3rd quarter. Barclays PLC now owns 117,973 shares of the company’s stock valued at $120,000 after purchasing an additional 75,780 shares during the period. Institutional investors and hedge funds own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.